An Intro to NAF’s New Chief Scientific Officer Role

NAF recently announced the hiring of Lauren Moore, PhD as its first Chief Scientific Officer. What does this role mean for Ataxia research? And what will she be doing at NAF? Join us to learn!

Feb 24, 2022
1:00 PM Central Time (US and Canada)

Register in advance for this meeting:
https://us02web.zoom.us/meeting/register/tZ0vceCrqTktGNV1_OJzSd-HLP96iosgw4WU

After registering, you will receive a confirmation email containing information about joining the meeting.

Lauren Moore, PhD has built a reputation as a collaborative and trusted colleague throughout the Ataxia research community. She was previously Senior Scientist at Exicure, a clinical stage biotech company where she acted as lead scientist over multiple therapeutic programs aimed at developing oligonucleotide-based therapies for rare neurological diseases such as Ataxia. She worked as a Graduate Research Assistant in the Rackham Graduate School at the University of Michigan under the mentorship of Dr. Henry Paulson. Dr. Moore received her PhD in neuroscience from the University of Michigan, where her thesis was titled “Towards understanding and developing antisense oligonucleotide-based therapies for spinocerebellar ataxia type 3.” She holds a B.S. in Biomedical Physics from Northeastern University.